… We sought to determine efficacy and safety of the association of IL-1 receptor antagonist
anakinra plus methylprednisolone in severe COVID-19 pneumonia with hyperinflammation. …

… and systemic hyperinflammation. Methods We conducted an open-label study of sarilumab
in severe COVID-19 pneumonia (PaO 2 /FiO 2 <300 mm Hg) with hyperinflammation (…

… During the 10-day follow-up, three cases of severe adverse events were recorded: two …
In conclusion, our series showed that COVID-19 pneumonia with ARDS was characterized …

… Endothelial dysfunction induces also increased oxidative stress and systemic inflammation,
glycocalyx degradation and shedding along with a pro-coagulant and anti-fibrinolytic state [9]…

… hyperinflammatory syndrome in severe COVID-19 is provided. The current evidence suggests
that the hyperinflammatory … to the hospital with COVID-19–related pneumonia in Wuhan, …

… unknown pneumonia named subsequently as coronavirus … of coexistence of hyperinflammation
and immunosuppression … about immune states of COVID-19 in severe patients and the …

… data see the Coronavirus Resource … COVID-19 pandemic. Accumulating evidence suggests
that a subgroup of patients with severe COVID-19 pneumonia develop a hyperinflammatory …

… of patients with COVID-19 pneumonia and hyperinflammation treated with mavrilimumab, …
in patients with COVID-19 pneumonia, hypoxaemia, and hyperinflammation. The primary …

… COVID-19 pneumonia (involving ≥20% of lung parenchyma on chest CT), hyperinflammation
(CRP … We reviewed all patients hospitalised for COVID-19 pneumonia when TCZ was not …

… In conclusion, the use of anakinra in patients with moderate hyperinflammation associated
with severe COVID-19 pneumonia after previous failure of corticosteroids alone or with …